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Abstract Tetramethylpyrazine (TMP) has been suggest-
ed to have neuroprotective effects against spinal cord in-
jury (SCI); however, few studies have examined these
effects and the corresponding mechanism. Therefore, the
present study aimed to investigate the neuroprotective ef-
fect and underlying mechanism of TMP against contusive
SCI. Adult male Sprague–Dawley rats were randomly di-
vided into Sham, normal saline (NS) and TMP groups.
Each group was divided into subgroups according to the
time of sacrifice: 1, 3, 7, 14, 21 and 28 days post-injury.
Laminectomy was performed in all groups, followed by
contusive SCI establishment in the TMP and NS groups.
TMP (80 mg/kg) was injected thereafter daily from 3 to
7 days post-injury in the TMP group, which was replaced
by equal volume of normal saline in the NS group. The
Basso–Beattie–Bresnahan (BBB) Locomotor Rating Scale
was measured at different time points post-injury to ap-
praise locomotor functional recovery. Quantitative real-
time PCR and immunofluorescence were used to assess the
spatio-temporal expression of peroxisome proliferator-ac-
tivated receptor-c coactivator-1a (PGC-1a), while western
blot was adopted to detect the effect of TMP on PGC-1a.
Neural apoptotic changes and neuronal survival were
evaluated using the TUNEL method and Nissl staining,
respectively. TMP treatment markedly increased PGC-1a
expression, neuronal survival and BBB locomotor scores,
while also reducing neural apoptosis. These results
demonstrate that TMP is neuroprotective against contusive
SCI, with the inhibition of neural apoptosis and increase of
neuronal survival. The sustained expression of PGC-1a
may partially contribute to the TMP-mediated neuropro-
tective effect.
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Introduction
Spinal cord injury (SCI), which is mostly caused by falls,
sports injuries or traffic accidents, is a devastating injury that
can lead to severe disability and lethal complications, in-
cluding pulmonary system impairment [1, 2]. Data indicates
that by the end of 2012, the prevalence of SCI across the
globe reached a maximum of 1298 per million inhabitants
[3]. Because of the large number of patients and severe
complications of the disease, scientists have placed great
effort into determining the underlying pathological
mechanisms, in hope of developing more effective treat-
ments. The complex course of SCI is mainly divided into the
primary and the secondary injuries [4]. To date, it is widely
accepted that the primary injury is an irreversible mechanical
damage, while the secondary injury is reversible with some
interventions. Thus, the major aim of SCI research is to de-
velop therapeutic interventions, through the understanding
of their mechanisms, to reduce and even reverse secondary
spinal cord damage, and to regain motor functions.
Although the precise mechanism of the secondary
pathogenic injury of SCI is still debatable, neuronal
apoptosis has been implicated as the most damaging
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factor, which can lead to disastrous consequences [5, 6].
Recent promising evidence suggests an intimate link
between peroxisome proliferator-activated receptor-c
coactivator-1a (PGC-1a) and neuronal survival in neu-
rological disorders, such as Alzheimer’s disease, Parkin-
son’s disease, amyotrophic lateral sclerosis and cerebral
ischemia [7–10]. PGC-1a is an important transcriptional
coactivator closely linked to energy metabolism, and is
involved in a variety of physiological and pathological
processes. It is reported that, in certain neurological
diseases, PGC-1a mainly plays a positive role by
regulating mitochondria [11], which are also closely in-
volved in regulating apoptosis [12, 13]. These studies
have provided us with good inspiration for the develop-
ment of SCI treatments. Although PGC-1a expression
has been previously reported, its expression in spinal
cord and alteration in SCI remain unclear. Further in-
vestigation is also required to determine if modulating its
expression through pharmacological or other treatments
has a positive impact on SCI.
For around a decade, our group has been researching
SCI and traditional Chinese medicine therapy. Tetram-
ethylpyrazine (TMP), which is of our particular interest, is
an important chemical constituent that is extracted from the
medicinal plant Ligusticum wallichii. It has been previ-
ously reported that TMP has a protective effect on the
nervous system [14–16], but the mechanisms are poorly
understood. Thus, the present study aimed to investigate
the effect and underlying mechanism of TMP on neuronal
protection closely related to PGC-1a activation in a
clinically relevant model of SCI.
Materials and Methods
Animals and Experimental Design
Adult male Sprague–Dawley rats, weighing 220–250 g,
were obtained from the Center of Experimental Animals,
Central South University. All surgical interventions, peri-
operative care and drug administrations were performed in
accordance with internationally accepted principles, and
were approved by the Animal Use and Ethics Committee of
Central South University. The rats were housed three (two
after SCI modeling) per laboratory cage, with free access to
food and water, in identical environments (temperature
22–24 C; humidity 60–80 %). The experimental rats were
randomly divided into the following three groups: Sham
group, normal saline (NS) group and TMP group. Each
group was divided into 6 subgroups (n = 10 per subgroup)
according to the time of sacrifice: 1, 3, 7, 14, 21 and
28 days post-injury (dpi).
Contusive Spinal Cord Injury Modeling
The establishment of contusive SCI model was performed
as previously described [17], with slight modification.
Briefly, the rats were intraperitoneally (i.p.) anesthetized
with chloral hydrate, following which they received con-
ventional skin preparation and antisepsis. Laminectomy
was performed at thoracic vertebra level 10 (T10) in all
groups, followed by contusive SCI of moderate severity
(8 g weight 9 3 cm vertical height free falling) in the NS
and TMP groups. Successful signs of contusive SCI mod-
eling were as follows: bleeding and edema in the T10
spinal cord, retracted flapping of both hind limbs, spas-
modic sway of the tail, and flaccid paralysis after
palinesthesia.
Drug Administration
TMP was purchased from Tianjin Jinyao Amino Acid Co.
Ltd., China. There were some differences in the effective
dosage of TMP among other published reports [14, 18].
Taking the therapeutic and side effects into consideration,
we ultimately chose 80 mg/kg as the application dosage in
this study. TMP was injected i.p. daily for 5 consecutive
days from day 3 post-injury in the TMP group, which was
replaced by equal volumes of normal saline in the NS
group.
Behavioral Assessment
Behavioral assessments were performed prior to surgery
and at 1, 3, 7, 14, 21 and 28 days post-injury in all three
groups, based on a 21-point Basso–Beattie–Bresnahan
(BBB) Locomotor Rating Scale, where 0 reflects no loco-
motion and 21 reflects normal motor functions [19]. Hind
limb movements, trunk position and stability, tail position,
stepping, coordination, paw placement and toe stretching
were all observed over a 5 min period for each rat, by two
independent examiners who were blinded to the ex-
perimental design.
Tissue Collection
Spinal cord tissues were mainly harvested by two methods.
The first method involved direct separation of about 1 cm
length of spinal cord tissue at T10, after the rats were
euthanized. The removed tissues were then immediately
preserved in liquid nitrogen. These tissues were used for
total RNA and protein extraction. The second method was
as follows: the rats were deeply anesthetized and perfused
with 300 ml 37 C heparinized normal saline, through the
ascending aorta, followed by 4 % paraformaldehyde (PFA)
in 0.1 M PBS; the spinal cord tissues around T10 were then
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carefully removed, post-fixed in 4 % PFA overnight at
4 C; serially dehydrated in 15 and 30 % sucrose solution
until sinking, the dehydrated tissues were thereafter em-
bedded in optimal cutting temperature (O.C.T.) compound,
and frozen at -20 C. The frozen O.C.T.-embedded tissues
were sectioned at a 10-lm thickness for immunofluores-
cence, TUNEL and Nissl assays.
Quantitative Real-Time PCR Analysis
Total RNA was extracted using the Trizol method, ac-
cording to the manufacturer’s instructions (Invitrogen,
USA). After reverse transcription was performed, quanti-
tative real-time PCR (qRT-PCR) was analyzed in a BIO-
RAD CFX96 Real-Time System, using SYBR Premix Ex
TaqTM II (Takara, Japan). The primers were designed using
NCBI primer-blast and synthesized by Sangon biotech-
nology (Shanghai, China) as follows: PGC-1a (forward:
GGA CAC GAG GAA AGG AAG ACT A; reverse: GTA
GCA CTG GCT TGA ATC TGT G) and b-actin (forward:
CCC ATC TAT GAG GGT TAC GC; reverse: TTT AAT
GTC ACG CAC GAT TTC). The specificity of PCR
products was guaranteed by melting curve analysis. The
expression of PGC-1a was normalized to b-actin, and the
gene expression was comparatively analyzed using the
2-DDCt method.
Western Blot Analysis
Total proteins were extracted using RIPA buffer and pro-
tease inhibitor phenylmethanesulfonyl fluoride (Beyotime,
China). Protein concentrations were determined using the
BCA method. Then, equal amounts of protein extracts were
separated in an 8 % gel by SDS-PAGE, followed by
transfer onto a polyvinylidene fluoride (PVDF) membrane.
Blocking was performed for 1 h with 5 % skim milk in
0.05 % Tween-20 in PBS (PBST) at room temperature.
Thereafter, the PVDF membrane was incubated with the
primary antibody in 5 % IgG-free BSA (Genview, USA)
overnight at 4 C, followed by incubation with the horse-
radish peroxidase-conjugated secondary antibody for 1 h,
after rinsing in PBST. Then, the membrane was rinsed in
washing buffer and the signal was detected with enhanced
chemiluminescence. Primary antibodies included PGC-1a
(Novus, USA; 1:1500) and b-actin (BBI, China; 1:1000).
Band intensities were quantified using Image J software.
Values were normalized to b-actin in all samples.
Immunofluorescence Assay
Immunofluorescence staining was performed on frozen
sections. In brief, sections were rinsed in PBS and treated
with 0.3 % Triton X-100 in PBS to disrupt the membranes.
After blocking with 10 % normal goat serum for 1 h to
reduce nonspecific staining, sections were incubated with
the primary antibodies, mouse anti-beta III tubulin (Ab-
cam, USA, 1:100) and rabbit anti-PGC-1a (Novus, USA,
1:150) overnight at 4 C for 24 h. After rinsing in PBS, the
secondary antibodies, Alexa Fluor 488 goat anti-mouse
IgG (H ? L) (Jackson, USA, 1:600) and Cy3 goat anti-
rabbit IgG (H ? L) (Jackson, USA, 1:800), were added
onto sections in 5 % blocking solution, to incubate at room
temperature for 30 min. Then, the sections were counter-
stained with DAPI (Sigma, USA), and imaged using a
Leica DFC310 FX microscope (Leica, Japan).
TUNEL Assay
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) staining was performed on
frozen sections, to detect apoptotic changes of neural cells
after contusive SCI, using the TUNEL staining apoptosis
detecting kit (Nanjing KeyGen Biotech Co. Ltd., China)
according to the manufacturer’s protocol. To reveal total
cells, we counterstained the same sections with hema-
toxylin. The number of TUNEL-positive and total neural
cells was counted in five different microscopic fields per
section, and the TUNEL-positive percentage was
calculated.
Nissl Assay
Nissl staining was performed on frozen sections 5 mm
rostrally to the lesion epicenter, with Nissl solution (0.1 %
Cresyl violet) for 20 min. After rinsing in distilled water,
the sections were differentiated in 95 % ethyl alcohol.
Then, the sections were rinsed in 70 % ethyl alcohol, de-
hydrated in increasing concentrations of ethyl alcohol, and
cleared in xylene. The cells containing Nissl bodies were
considered as neurons, and those with typical neuronal
morphology were counted per section. One out of every
two sections was taken and a total of five sections were
counted for each group to determine neuronal survival. A
typical neuron exhibited a large amount of granule-like
dense bluish violet staining indicating Nissl bodies in a
regularly polygonal cell body. In a damaged neuron, Nissl
bodies decreased in number and density, and the cell body
became relatively small and irregular.
Statistical Analysis
Statistical analysis was performed using SPSS 19.0 soft-
ware (IBM, USA). Data were presented as the
mean ± standard deviation (SD). The statistical sig-
nificance of differences was determined using one-way
analysis of variance (ANOVA) followed by Bonferroni
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post hoc test for multiple comparisons, or Student’s un-
paired t test between two groups. All analyses were based
on at least three different experiments with duplicate
samples. A value of P\ 0.05 was considered to be sta-
tistically significant.
Results
Effect of TMP on Locomotor Function Recovery
We first examined the effect of TMP on the recovery of
locomotor functions. To obtain a holistic view, BBB Lo-
comotor Rating Scale was implemented in a relatively
systematic observation period. In our study, BBB scores
were performed both prior to injury and at 1, 3, 7, 14, 21
and 28 days post-injury.
As shown in Fig. 1, locomotor functions of rats exhib-
ited a 21-point non-injured score in the Sham group. After
contusive SCI, BBB locomotor rating scale was promptly
decreased. At 1 day post-injury, BBB scores exhibited
around two points. As the healing process progressed, a
gradual recovery of locomotor functions could be found in
both the NS and TMP groups, but the scores were sig-
nificantly higher in TMP group at 7–28 days post-injury.
TMP treatment markedly increased the recovery rate of
locomotor function in rats with contusive SCI. Importantly,
the fastest functional recovery occurred between days 3
and 7 post-injury in the TMP group. This showed that the
administration of TMP was effective within this period,
and correlated with the locomotor functional recovery at
later time periods.
Effect of TMP on PGC-1a Expression
Firstly, we investigated PGC-1a expression in physio-
logical (as control) and injured spinal cord tissues, without
any intervening measures. Following this, we examined
whether any changes in expression occurred following
TMP administration in a contusive SCI model, to better
illustrate the intrinsic mechanism of the drug. We used
qRT-PCR to assess PGC-1a expression in the T10 spinal
cord at different time points. The spatial expression of
PGC-1a was also examined by immunofluorescence
staining.
Overall, PGC-1a expression significantly decreased
after contusive SCI, followed by a gradual increase, in
correlation with the spontaneous repair, until it reached a
plateau. Specifically, relative to the normal control, the
PGC-1a expression at 1 day post-injury decreased by about
80 %. From 7 days post-injury, an obvious increase oc-
curred, but the expression level was still less than 60 % of
the normal control at the end of our observation (Fig. 2).
PGC-1a expression was mainly located in the grey matter
of normal spinal cord. Besides, there was a high degree of
overlap between neurons and PGC-1a, particularly in the
ventral horn, while double staining devoid of neuronal
marker could also be found. After injury, the main co-
localization of neurons and PGC-1a could still be discov-
ered despite the morphological abnormalities of the pre-
served neurons (Fig. 3). It is highly possible that PGC-1a
plays a role of neuronal origin in protecting spinal cord
homeostasis.
Fig. 1 Effect of tetramethylpyrazine (TMP) on locomotor functional
recovery. Prior to spinal cord injury (SCI), the Basso–Beattie–
Bresnahan (BBB) scores of rats in both the TMP (n = 5) and normal
saline (NS) (n = 5) groups were 21 points, which is the same score
the sham group remains at for all time points. After contusive SCI, the
BBB scores of rats in the NS and TMP groups rapidly decreased and
then gradually increased. From 7 to 28 days post-injury, the BBB
scores in the TMP group were significantly higher than the NS group.
The fastest locomotor functional restoration occurred from 3 to
7 days post-injury in the TMP group. **P\ 0.01 comparisons
between the TMP and NS groups
Fig. 2 Quantitative RT-PCR analysis of the temporal expression of
PGC-1a. It shows that after contusive spinal cord injury (SCI)
(n = 3), PGC-1a expression in spinal cord significantly decreased
compared with that of normal control (n = 3), followed by a gradual
increase from 7 days post-injury (dpi). All expressions were normal-
ized to b-actin. *P\ 0.05, **P\ 0.01 comparisons between each
SCI group and the control group
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Intriguingly, PGC-1a expression was significantly
higher in the TMP group than the NS group at 3, 7, 21, and
28 days post-injury (Fig. 4). This showed TMP treatment
significantly upregulated PGC-1a expression in injured
spinal cord tissues.
Effect of TMP on Neural Apoptosis and Neuronal
Survival
TMP significantly increased PGC-1a expression, especially
at days 3 and 7 post-injury, and promoted fastest locomotor
functional recovery; therefore, we believe that this is a
crucial period for repairing the injured spinal cord with
TMP treatment. We collected spinal cord tissues at 3 and
7 days post-injury to detect whether tissues in the TMP
group exhibited less apoptosis and more survival.
The apoptotic change of neural cells was measured by
TUNEL staining. In the Sham group, there was minimal
apoptosis, so the TUNEL-positive percentage was ex-
tremely low. In contrast, the TUNEL-positive percentage
was high in both the NS and TMP groups. However, TMP
treatment significantly decreased the apoptosis rate of
Fig. 3 Immunofluorescence staining of the spatial expression of
PGC-1a. The first row of images (a–c) demonstrates that PGC-1a is
mainly expressed in the grey matter of the spinal cord in normal rats,
and has a main co-localization with the neurons in the ventral horn.
The b-III tubulin antibody was used to detect neurons. White arrow
heads indicate the representative expression location of PGC-1a, and
white arrows are representative of its co-localization with the
neuronal marker. Double-staining at higher magnification in the
second and third rows of images (d–i) clearly shows predominant
overlap between neurons and PGC-1a in spinal cord tissues both pre-
and post-contusive spinal cord injury. Scale bar 20 lm
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contusive SCI. At 7 days post-injury the TUNEL-positive
percentage was approximately 28 and 11 %, respectively in
the NS group and TMP group; the apoptosis rate of the
TMP group decreased by about 60 % relative to the NS
group (Fig. 5).
Next, we detected whether there was any difference in
neuronal survival at 7 days post-injury using Nissl staining.
Our results demonstrate that there were markedly more
Nissl-positive cells with good morphology in the TMP
group compared with that of the NS group (Fig. 6). This
Fig. 4 Effect of tetramethylpyrazine (TMP) treatment on PGC-1a
expression. The quantitative data (a) and representative protein bands
(b) of the western blot analysis of PGC-1a expression indicate that
TMP treatment (n = 5) significantly increased the expression of
PGC-1a at 3, 7, 21 and 28 days post-injury (dpi) compared with
normal saline (NS) treatment (n = 5). **P\ 0.01 comparisons
between the TMP and NS groups
Fig. 5 Effect of
tetramethylpyrazine (TMP)
treatment on neural apoptosis.
Representative TUNEL staining
(a) shows that apoptotic cells in
T10 spinal cord were minimal in
the sham group, but numerous
in the normal saline (NS) and
TMP groups. At 7 days post-
injury (dpi), the apoptotic rate
decreased in the TMP group
compared with that of the NS
group. Cell nuclei are stained
blue. Black arrows indicate
typical positive apoptotic
staining. Scale bar 50 lm. The
quantitative data (b) shows that
the TUNEL-positive percentage
in the TMP group (n = 5) was
significantly lower than the NS
group (n = 5) at 7 dpi.
**P\ 0.01 comparison
between the TMP and NS group
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showed that TMP treatment promoted the survival of
neurons after contusive SCI.
Discussion
In the present study, we evaluated the neuroprotective ef-
fect of TMP on contusive SCI in a rat model. Our data
showed for the first time that the expression of PGC-1a in
spinal cord was decreased after contusive SCI. Following
TMP treatment, there was a significant improvement in
neurological recovery, as demonstrated by the BBB scores
test, from day 3 post-injury. This neuroprotective effect
was accompanied by a reduction of neural apoptosis, and
increased PGC-1a expression and neuronal survival in
TMP-treated animals. These findings indicate that the
neuroprotective effect of TMP in contusive SCI may occur
through the sustained expression of PGC-1a.
Clinically, the recovery of locomotor function is a key
indicator of a better prognosis for SCI patients. It is also
acknowledged that even a slight enhancement of locomotor
function could bring considerable benefits to severely
paralyzed patients. In the scientific field of SCI, the BBB
Locomotor Rating Scale is the most widely accepted and
commonly used open field test to evaluate motor function.
Hence, we adopted this method in our study to assess the
changes of motor function in rat models of contusive SCI,
which is similar to the human condition [20]. Meanwhile, it
has been suggested that integration of the CatWalk-based
coordination method into the BBB Locomotor Rating Scale
guarantees the validness of locomotor function assessment
[21]. It is a reasonable suggestion, but the enormous value
of BBB assessment by itself cannot be argued against. It
has certain advantages, such as the exclusion of rats with
incomplete damage and the revealing of a key period when
maximum functional recovery occurred in our study, thus
providing us with an affirmative scenario that the treatment
of TMP on SCI is an efficient therapy.
TMP was initially used as a traditional medicine to
improve blood circulation and remove blood stasis in the
treatment of cerebral thrombosis, coronary heart disease,
angiitis, and other disorders. Recently, it has been sup-
ported by several studies that TMP also plays a direct role
in protecting neural tissue and cells [14, 15, 22]. Increasing
emphasis is being placed on the application of TMP in
neurovascular diseases. Nevertheless, because of the lack
of publications on the molecular mechanism of TMP in the
treatment of SCI, further investigation is still needed to
elucidate the specific regulatory mechanism and lay the
foundation for its extended clinical application. Following
the mounting evidence on the role of PGC-1a in neuro-
logical diseases of the brain, we decided to investigate if
PGC-1a expression changes after contusive SCI, and if
TMP treatment also affects its expression. Comparing to
normal spinal cord, PGC-1a expression after SCI sig-
nificantly decreased and did not return to normal levels by
Fig. 6 Effect of
tetramethylpyrazine (TMP)
treatment on neuronal survival.
Representative Nissl staining
(a) shows that at 7 days post-
injury there were more
surviving neurons in the TMP
group than in the NS group,
which were closer to the
neurons in the Sham group. The
mottled bluish violet stained
typical morphological features
of cells indicates neurons. Inside
the black box are the examples
of each group. Scale bar
100 lm. The quantitative data
(b) demonstrates that the TMP
group (n = 5) displayed a
significantly increased number
of neurons compared with that
of the NS group (n = 5) at
7 days post-injury. **P\ 0.01
comparison between the TMP
and NS group
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the end of our observation period. These data are of par-
ticular importance, as it indicates that PGC-1a has a cor-
relation with the physiological function of spinal cord.
Thus, we further investigated the impact of TMP treat-
ment on PGC-1a expression following SCI. In fact, the
gene of PGC-1a has multiple regulatory points and its
transcriptional co-activation can be manipulated in com-
bination with protein modification [23]. It is also well-
known that the protein is the function executor of a specific
gene, so western blot was the mainly adopted method to
assess the effect of TMP on PGC-1a expression. Our re-
sults demonstrate that TMP can sustain the expression of
PGC-1a in injured spinal cord. Moreover, PGC-1a is more
likely to originate from neurons in the spinal cord, as we
find that it mainly located in neurons in both normal and
injured tissues. Meanwhile, the possibility of other origin
such as glial cells cannot be excluded, since PGC-1a ex-
pression location does not totally overlap with neurons.
Our results are similar to a study of amyotrophic lateral
sclerosis, in which it is also speculated that the protective
effects of PGC-1a are of neuronal rather than glial origin
[9]. Furthermore, the TUNEL assay and Nissl staining re-
sults support the hypothesis that TMP treatment may par-
tially regulate the PGC-1a expression at the protein level to
protect against SCI.
To date, the specific association between PGC-1a ex-
pression and contusive SCI has not been elucidated. PGC-
1a is a critical transcriptional co-activator enriched in
mitochondria-rich tissues, and serves as an important
regulator of cellular energy metabolism [24, 25]. However,
the cellular effects of PGC-1a require the targeting of
specific transcription factors, such as estrogen-related re-
ceptor-a (ERR-a), which has strong synergistic effects on
PGC-1a activity [26, 27]. Nuclear respiratory factors
(NRF-1/-2) are considered to be classical factors control-
ling the mitochondrial regulation of PGC-1a activity;
however, ERR-a is believed to also influence mitochon-
drial gene expression and function in parallel to NRF-1/-2
dependent pathways [28]. By interacting with ERR-a,
PGC-1a may have a direct effect on mitochondria in
neurons following SCI. Another possible mechanism is that
vascular endothelial growth factor (VEGF) mediates the
final neuroprotection. ERR-binding sites have been iden-
tified within the VEGF promoter, and VEGF is perceived
as a direct transcriptional target of the PGC-1a/ERR-a
pathway [29, 30]. It is well known that VEGF is a critical
factor in stimulating angiogenesis, but growing evidence
suggests that the increased VEGF can directly induce
neurotrophic and neuroprotective effects, which may be
partially realized through binding to its receptor Flk-1 [31–
33].
The treatment of SCI has never been an easy task. The
central nervous system (CNS) is very complex, with neural
and vascular components that are closely linked to each
other, despite the existence of blood–brain barrier or blood-
spinal cord barrier. Recently, the concept of the neu-
rovascular unit (NVU) has drawn increasing attention to
the comprehensive influence of neural and vascular factors
on CNS diseases. The NVU, which consists of cellular and
non-cellular compositions, including neurons, glia, mi-
crovessels, pericytes and the extracellular matrix, was ini-
tially been suggested to enhance the overall understanding
of stroke [34, 35]. Now, more and more emphasis has been
put on it when dealing with CNS diseases. This change in
perception of the NVU is largely a result of investigations
targeting the individual involvement of blood vessels or
nerve factors in CNS repair not harvesting significant
therapeutic effects. It is believed that the NVU is also
present in the spinal cord, although morphological and
functional differences exist between the blood–brain and
blood-spinal cord barriers [36, 37]. Intriguingly, PGC-1a
appears to be a factor that can exert a positive influence
both on neural and vascular compositions. This speculation
is supported by a recent in vitro study, where PGC-1a
played a beneficial role in hypoxic preconditioning to both
endothelial and neuronal cells [38]. In our future research,
we will also focus on whether PGC-1a has a vascular
protective effect. This is of particular importance, as if this
gene has a unique capacity to exert multiple influences on
neurovascular compositions of the spinal cord, the tradi-
tional Chinese medicine TMP could provide a powerful
tool to efficaciously treat SCI.
In conclusion, our data implicate the spatial and temporal
expression of PGC-1a in rat models of contusive SCI. We
also highlight for the first time that the TMP-mediated in-
duction of neuroprotective responses against SCI may partly
involve sustaining PGC-1a expression. Although further
research is needed to elucidate the entire signaling pathway,
our present study provides strong support for the use of TMP
treatment in SCI. These data may facilitate a better under-
standing of the benefits of TMP and warrant further study of
this drug for the treatment of neurovascular diseases.
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